Newsletter Signup
Where current and emerging technology trends meet.
TecTrendsInformation Sources, Inc.
  | About TecTrends | Email Signup | Contact Us
 Live Search:
Live Search | Articles | Companies | TecTerms | Products
  Loading TecTrends Live Search - please wait... 
View Noteworthy Articles      PRNewswire
 
Company

Ablynx nv
Technologiepark 4
Ghent - Zwijnaarde,  BE  09052
Belgium
Telephone: 9 261 06 32
Fax: () 9 261 06 28
URL: http://www.ablynx.com/
Email: info@ablynx.com

Ablynx, founded in 2001 and based in Ghent, Belgium, is a biopharmaceutical company known for its Nanobody (TM) therapeutic proteins, which are derived from antibodies. The proteins combine the features of antibody therapeutics and small-molecule drugs. The company's Nanoclone (TM) methodology supports the isolation of Nanobodies (TM). Nanoclone identifies antigen-specific proteins. The Nanobodies have low immunogenic potential, supporting their use in therapies. Ablynx holds U.S. and European composition of matter patents on its technology. Ablynx was spun off from the Flanders Interuniversity Institute of Biotechnology. Company investors include Alta Partners, Abingworth Management, GIMV, Sofinnova Partners, and Glide Investment Management. The firm has raised over $40 million in capital. Ablynx is focusing on developing Nanobodies that treat thrombosis, immune disorders, and neurodegenerative disease.

Equity Type: Private
Company Status: Active Date Founded: 2001

TecTerms:
 


Home About TecTrends About Us Contact Us Privacy Statement Terms and Conditions

TecTrends | P.O. Box 8120 | Berkeley CA 94707 | (510) 525-6220 | Email: tectrends@tectrends.com
© 2006 INFORMATION SOURCES INC | All rights reserved.